Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Intra-Cellular Form 4 April 04, 201	Therapies, Inc.										
FORM	Л	TATES SECI	SECUDITIES AND EXCHANCE COMMISSION						OMB APPROVAL		
Check this		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235-0287		
if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er STATEM 6. Filed purst ¹⁵ Section 17(a)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESExpires:January 20Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940Expires:January 20									
(Print or Type Responses)											
1. Name and A RIGGS ROF	ddress of Reporting Po XY B	Symbol	er Name and Cellular The			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Mi		3. Date of Earliest Transaction								
C/O INTRA THERAPIES 29TH STRE	03/31/	(Month/Day/Year) 03/31/2016				_X_Director10% Owner Officer (give titleOther (specify below)below)					
NEW YORK	(Street) 5, NY 10016	nendment, Da onth/Day/Year)	-			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		Zip) Ta	ble I - Non-D	erivative S	Securit	ties Ac	quired, Disposed o	of, or Beneficia	llv Owned		
1.Title of Security (Instr. 3)		ansaction Date 2A. Deemed hth/Day/Year) Execution Date, any		3. 4. Securities			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of		
Common Stock	03/31/2016		A	382	(D) A	\$ 0	16,061	D			
Common Stock							240,955	I	Held by New Ventures I, LLC (1)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

1

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	• •	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur (Instr	Amount or	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	(A) (D)				Shares		
Repo	rting O	wners									
I	Reporting Ow	vner Name / Address		Relat	tionships						
			Director	r 10% Ow	wner Offi	icer Other					
430 EAST NEW YO	RA-CELLU T 29TH STI ORK, NY 10		S, INC. X								
Signa	tures										

/s/ Lawrence J. Hineline, Attorney-in-fact 04/04/2016

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Mr. Riggs is Managing Member of New Ventures I, LLC and may be deemed to beneficially own the securities held by New Ventures I,(1) LLC. Mr. Riggs disclaims beneficial ownership of the securities held by New Ventures I, LLC except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.